Results from the study confirm that Ig use increased between 2009 and 2019, in both the commercially-insured and Medicare populations. Increases were observed in:
- the number of Ig administrations
- the number of enrollees receiving Ig
- the annual number of administrations per recipient
- the average aggregate annual dose
- the average dose per administration (to a lesser extent)
To read the full Executive Summary, click here.